COPD
Conditions
Interventions
The intervention group will receive vitamin D3 1200 IU orally once a day. The control group will receive a placebo orally once a day.
Sponsors
VU University Medical Centre
Eligibility
Inclusion criteria
Inclusion criteria: 1. Written informed consent; 2. Aged between 40 and 75 years; 3. Diagnosis COPD performed by the pulmonologist; 4. Vitamin D deficiency (defined as a serum 25-hydroxyvitamin D < 50 nmol/l).
Exclusion criteria
Exclusion criteria: 1. Severe vitamin D deficiency (serum 25-hydroxyvitamin D <15 nmol/L); 2. Life expectation of less than 6 months on the basis of concurrent disease; 3. Interfering malignant diseases; 4. Serious mental impairment i.e. preventing to understand the study protocol or comply with the study aim; potentially unreliable patients and those judged by the investigator to be unsuitable for the study; 5. Pregnant or lactating women, or subjects who intend to become pregnant within the study period.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The main study parameters are the serum concentration 25-hydroxyvitamin D, the pulmonary function parameters FEV1 and FVC, the incidence of airway infections, the scores on the physical performance tests and the scores on the LASA physical activity questionnaire (LAPAQ). | — |
Contacts
Public ContactP. Lips
VU Medical Center, Department of Endocrinology, P.O. Box 7057
Outcome results
None listed